Cargando…
High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
PURPOSE: Although programmed death-ligand 1 (PD-L1) expression is widely accepted as a predictive and prognostic biomarker in immunotherapy, its implications in lung cancer patients with driving mutations are still unclear. The objective of this study is to determine the association between PD-L1 ex...
Autores principales: | Yoon, Byung Woo, Chang, Boksoon, Lee, Seung Hyeun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445533/ https://www.ncbi.nlm.nih.gov/pubmed/32903896 http://dx.doi.org/10.2147/OTT.S271011 |
Ejemplares similares
-
Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy
por: Kwack, Won Gun, et al.
Publicado: (2021) -
High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
por: Sung, Ji-Youn, et al.
Publicado: (2022) -
Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study
por: Chang, Boksoon, et al.
Publicado: (2021) -
Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
por: Hwang, In Kyoung, et al.
Publicado: (2019) -
Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
por: Cai, Yiran, et al.
Publicado: (2020)